



Analytical method development and validation for the estimation of Lisinopril by reverse-phase high-performance liquid chromatography

Y Ganesh Kumar ^{1*}, G Sruthi ², Ejajahmed ³, Md. Sahin Ali ⁴, Malipatel Mani Vardhan Reddy ⁵

¹⁻⁵ Department of Pharmaceutical Analysis, Sree Dattha Institute of Pharmacy, Sagar Road, Sheriguda, Ibrahimpatnam, Telangana, India

* Corresponding Author: Y Ganesh Kumar

Article Info

ISSN (online): 2582-7138

Volume: 03

Issue: 06

November-December 2022

Received: 28-10-2022

Accepted: 19-11-2022

Page No: 469-475

Abstract

A simple isocratic RP-HPLC method has been developed and subsequently validated for the determination of Lamivudine in API form and pharmaceutical dosage forms as per ICH guidelines. The separation achieved on a reversed phase Symmetry ODS (C18) RP Column, 250 mm x 4.6 mm, 5 μ m as a stationary phase and Phosphate Buffer and Methanol in the ratio of 46:54 (pH-3.2) as mobile phase at a flow rate of 1.0 ml/min. The UV detection was performed at 206 nm. The retention time for Lamivudine was found to be 3.622min. The detector response was linear in the concentration range of 60-140 μ g/ml. The respective linear regression equation being $Y = 48313.x + 71968$ with $R^2 = 0.9993$. The percentage of Lamivudine in pharmaceutical dosage form was found to be within in the limits. The limit of detection and the limit of quantification were found to be 0.08 μ g/ml and 0.24 μ g/ml respectively. The results of the study showed that, the proposed RP-HPLC method was simple, rapid, precise, accurate and specific, which can be used for the routine determination of Lamivudine in API form and pharmaceutical dosage form.

Keywords: In API form and, RP-HPLC, method development, validation, ICH guidelines

Introduction

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor widely used in the therapy of hypertension and heart failure. Lisinopril ^[1] is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury that can be severe and even fatal. Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patient's ≥ 6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension. Lisinopril ^[2] is an angiotensin converting enzyme inhibitor used to treat hypertension, heart failure, and myocardial infarction. Lisinopril is not a prodrug, and functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. It has a wide therapeutic index and a long duration of action as patients are generally given 10-80mg daily. Angiotensin II constricts coronary blood vessels and is positively inotropic, which under normal circumstances, would increase vascular resistance and oxygen consumption. This action can eventually lead to myocyte hypertrophy and vascular smooth muscle cell proliferation. Lisinopril ^[3] is an angiotensin converting enzyme inhibitor (ACEI), preventing the conversion of angiotensin I to angiotensin II. This action prevents myocyte hypertrophy and vascular smooth muscle cell proliferation seen in untreated patients. Increased levels of bradykinin also exhibit vasodilating effects for patients taking ACEIs. Lisinopril also inhibits renin's conversion of angiotensin to angiotensin I. Lisinopril is used alone or in combination with other medications to treat high blood pressure in adults and children 6 years of age and older. It is used in combination with other medications to treat heart failure. Lisinopril is also used to improve survival after a heart attack. The IUPAC Name of Lisinopril is (2S)-1-[(2S)-6-amino-2-[[[(1S)-1-carboxy-3-phenyl propyl] amino] hexanoyl] pyrrolidine-2-carboxylic acid. The Chemical Structure of Lisinopril is as following.




Fig 1: Chemical Structure of Lisinopril

Experimental

Table 1: List of Instrument used

S. No.	Instruments/Equipments/Apparatus
1.	HPLC with Empower2 Software with Isocratic with UV-Visible Detector (Waters).
2.	T60-LAB INDIA UV – Vis spectrophotometer
3.	Electronic Balance (SHIMADZU ATY224)
4.	Ultra Sonicator (Wensar wuc-2L)
5.	Thermal Oven
6.	Symmetry ODS RP C ₁₈ , 5 μ m, 15mm x 4.6mm i.d.
7.	P ^H Analyzer (ELICO)
8.	Vacuum filtration kit (BOROSIL)

Table 2: List of Chemicals used

S. No.	Name	Specifications		Manufacturer/Supplier
		Purity	Grade	
1.	Doubled distilled water	99.9%	HPLC	Sd fine-Chem ltd; Mumbai
2.	Methanol	99.9%	HPLC	Loba Chem; Mumbai.
3.	Dipotassium hydrogen orthophosphate	96%	A.R.	Sd fine-Chem ltd; Mumbai
4.	Acetonitrile	99.9%	HPLC	Loba Chem; Mumbai.
5.	Potassium dihydrogen orthophosphate	99.9%	A.R.	Sd fine-Chem ltd; Mumbai
6.	Sodium hydroxide	99.9%	A.R.	Sd fine-Chem ltd; Mumbai
7.	Hydrochloric acid	99.9%	A.R.	Loba Chem; Mumbai.
8.	Hydrogen Peroxide	99.9%	A.R.	Loba Chem; Mumbai.

Selection of Wavelength

The standard & sample stock solutions were prepared separately by dissolving standard & sample in a solvent in mobile phase [4] diluting with the same solvent. (After optimization of all conditions) for UV analysis. It scanned in the UV spectrum in the range of 200 to 400nm. This has been performed to know the maxima of Lisinopril, so that the same wave number can be utilized in HPLC UV detector for estimating the Lisinopril. The scanned UV spectrum is attached in the following page,

Sample & Standard Preparation for the UV-Spectrophotometer Analysis

25 mg of Lisinopril standard was transferred into 25 ml

volumetric flask, dissolved & make up to volume with mobile phase.

Further dilution was done by transferring 0.5 ml of the above solution into a 10ml volumetric flask and make up to volume with mobile phase.

Optimization of Chromatographic Conditions

The chromatographic conditions were optimized by different means. (Using different column, different mobile phase, different flow rate, different detection wavelength & different diluents for sample preparation etc.

Table 3: Summary of Process Optimization

Column Used	Mobile Phase	Flow Rate	Wave length	Observation	Result
Symmetry C ₁₈ , ODS, Reverse Phase, 250 mm x 4.6 mm, 5 μ m, Column.	Methanol: Acetonitrile = 40: 60	1.0 ml/min	235 nm	Very Low response	Method rejected
Symmetry C ₁₈ , ODS, Reverse Phase, 250 mm x 4.6 mm, 5 μ m, Column.	Methanol: Acetonitrile = 55: 45	1.0 ml/min	235 nm	Low response	Method rejected
Symmetry C ₁₈ , ODS, Reverse Phase, 250 mm x 4.6 mm, 5 μ m, Column.	Acetonitrile: Water = 50:50	1.0 ml/min	235 nm	Tailing peaks	Method rejected
Symmetry C ₁₈ , ODS, Reverse Phase,	Methanol: Water = 70:30	1.0 ml/min	235 nm	Resolution was not good	Method rejected

250 mm x 4.6 mm, 5 μ m, Column.					
Symmetry C ₁₈ , ODS, Reverse Phase, 250 mm x 4.6 mm, 5 μ m, Column.	ACN : Methanol: 0.1% OPA = 70:25:5	1.0 ml/min	235 nm	Tailing peak	Method rejected
Symmetry C ₁₈ , ODS, Reverse Phase, 250 mm x 4.6 mm, 5 μ m, Column.	ACN : Methanol: 0.1% OPA = 60:30:10	1.0 ml/min	235 nm	Nice peak	Method accepted

Preparation of Mobile Phase

600ml of HPLC Grade Acetonitrile, 300ml of HPLC Grade Methanol and 100ml 0.1% OPA were mixed well and

degassed^[5] in ultrasonic water bath for 15 minutes. The solution was filtered through 0.45 μ m filter under vacuum filtration.

Results and Discussion

Method Development

Selection of Wavelength




Fig 2: UV Spectrum for Lisinopril

Observation: While scanning the Lisinopril solution we observed the maxima at 235nm. The UV spectrum has been recorded on T60-LAB INDIA make UV-Vis spectrophotometer model UV-2450.

Summary of Optimized Chromatographic Conditions

The Optimum Chromatographic conditions⁶ obtained from experiments can be summarized as below:

Table 4: Summary of Optimised Chromatographic Conditions

Mobile phase	ACN : Methanol: 0.1% OPA = 60:30:10
Column	Symmetry ODS (C ₁₈) RP Column, 250 mm x 4.6 mm, 5 μ m
Column Temperature	Ambient
Detection Wavelength	235 nm
Flow rate	1.0 ml/ min.
Run time	06 min.
Temperature of Auto sampler	Ambient
Diluent	Mobile Phase
Injection Volume	10 μ l
Type of Elution	Isocratic
Retention time	2.570 minutes




Fig 3: Chromatogram for Blank Solution




Fig 4: Chromatogram of Lisinopril in Optimized Condition

Method Validation

1. Accuracy

Recovery study

To decide the exactness ^[7] of the proposed strategy, recuperation thinks about were done by including diverse

sums (80%, 100%, and 120%) of unadulterated medication ^[8] of LISINOPRIL were taken and added to the pre-broke down plan of fixation 10 μ g/ml. From that rate recuperation ^[9] esteems were computed. The outcomes were appeared in table-5.

Table 5: Readings of Accuracy

Conc. In ppm	Conc. Found	Peak Area	% Recovery
8	8.035	161523	100.437
8	8.153	163815	101.912
8	8.061	162023	100.762
		Avg.	101.037
		S.D	0.775
		%RSD	0.767046
Conc. In ppm	Conc. Found	Peak Area	% Recovery
10	9.930	198315	99.30
10	10.033	200320	100.33
10	10.044	200540	100.44
		Avg.	100.0233
		S.D	0.628835
		%RSD	0.628688
Conc. In ppm	Conc. Found	Peak Area	% Recovery
12	11.981	238151	99.841
12	12.066	239819	100.55
12	12.215	242712	101.791
		Avg.	100.7273
		S.D	0.987021
		%RSD	0.979894

2. Precision

2.1. Repeatability

The precision ^[10] of each method was ascertained separately from the peak areas & retention times obtained by actual determination of six replicates of a fixed amount of drug, Lisinopril (API). The percent relative standard deviation ^[11-12] was calculated for Lisinopril are presented in the table-6.

Table 6: Readings of Repeatability

HPLC Injection Replicates of Lisinopril	Retention Time (Minutes)	Peak Area (AUC)
Replicate – 1	2.572	197236
Replicate – 2	2.570	197762
Replicate – 3	2.573	195969
Replicate – 4	2.570	194724
Replicate – 5	2.574	198327
Replicate – 6	2.573	198711
Average		197121.5
Standard Deviation		1515.213
% RSD		0.768667

2.2. Intermediate Precision

2.2.1. Intra-assay & inter-assay

The intra & inter day variation ^[13-16] of the method was carried out & the high values of mean assay & low values of standard deviation & % RSD (% RSD < 2%) within a day & day to day variations for Lisinopril revealed that the proposed method is precise.

Table 7: Results of Intra-Assay & Inter-Assay

Conc. Of Lisinopril (API) (μ g/ml)	Observed Conc. of Lisinopril (μ g/ml) by the proposed method			
	Intra-Day		Inter-Day	
	Mean (n=6)	% RSD	Mean (n=6)	% RSD
8	7.46	0.62	8.05	0.96
10	10.87	0.85	9.43	0.71
12	11.81	0.92	12.04	0.65

3. Linearity & Range

The calibration curve showed good linearity¹⁷ in the range of 6-14 μ g/ml, for Lisinopril (API) with correlation coefficient

[18-19] (r^2) of 0.999 (Fig-5). A typical calibration curve [20] has the regression equation of $y = 19423x + 5444$ for Lisinopril.




Fig 5: Calibration Curve of Lisinopril (API)

Table 8: Linearity Results

CONC.($\mu\text{g/ml}$)	MEAN AUC (n=6)
0 ppm	0
6 ppm	129013
8 ppm	166523
10 ppm	198315
12 ppm	234151
14 ppm	275819

4. Methods Robustness

Influence of small changes in chromatographic conditions [21] such as change in flow rate [22] ($\pm 0.1\text{ml/min}$), Wavelength of detection ($\pm 2\text{nm}$) & organic phase in mobile phase ($\pm 5\%$) studied to determine the robustness [23] of the method are also in favour of (Table-9, % RSD < 2%) the developed RP-HPLC method for the analysis [24] of Lisinopril (API).

Table 9: Result of Method Robustness Test

Change in parameter	% RSD
Flow (1.1 ml/min)	0.68
Flow (0.9 ml/min)	0.39
More Organic	0.54
Less Organic	0.63
Wavelength of Detection (237 nm)	0.91
Wavelength of detection (233 nm)	0.93

5. LOD & LOQ

The Minimum concentration level at which the analyte can be reliably detected (LOD) [25] & quantified (LOQ) [26] were found to be 0.08 & 0.24 $\mu\text{g/ml}$ respectively.

6. System Suitability Parameter

Framework appropriateness testing [27] is an essential piece of numerous scientific techniques. The tests depend on the idea that the gear, hardware, explanatory activities and tests to be broke down establish a vital framework that can be assessed all things considered. Following framework appropriateness test [28] parameters were built up. The information is appeared in Table-10.

Table 10: Data of System Suitability Parameter

S. No.	Parameter	Limit	Result
1	Resolution	$R_s > 2$	8.47
2	Asymmetry	$T \leq 2$	Lisinopril=0.23
3	Theoretical plate	$N > 2000$	Lisinopril=2987
4	Tailing Factor	$T < 2$	Lisinopril=1.17

7. Estimation of Lisinopril in Pharmaceutical Dosage Form

Twenty pharmaceutical dosage forms were taken and the I.P. strategy was taken after to decide the normal weight [29]. Above measured tablets were at last powdered and triturated well. An amount of powder proportionate to 25 mg of medications were exchanged to 25 ml volumetric flagon, make and arrangement was sonicated for 15 minutes, there after volume was made up to 25 ml with same dissolvable. At that point 10 ml of the above arrangement was weakened to 100 ml with versatile stage. The arrangement was separated through a layer channel (0.45 μm) and sonicated to degas [30]. The arrangement arranged was infused in five reproduces into the HPLC framework and the perceptions were recorded. A copy infusion of the standard arrangement was additionally infused into the HPLC framework and the peak regions were recorded. The information is appeared in Table-11.

$$\text{Assay \%} = \frac{AT}{AS} \times \frac{WS}{DS} \times \frac{DT}{WT} \times \frac{P}{100} \times \text{Avg. Wt} = \text{mg/tab}$$

Where:

AT = Peak Area of medication acquired with test arrangement

AS = Peak Area of medication acquired with standard arrangement

WS = Weight of working standard taken in mg

WT = Weight of test taken in mg

DS = Dilution of Standard arrangement

DT = Dilution of test arrangement

P = Percentage virtue of working standard

Table 11: Recovery Data for estimation Lisinopril in Zestril 10

Brand Name of Lisinopril	Labelled amount of Drug (mg)	Mean (\pm SD) amount (mg) found by the proposed method (n=6)	Assay % (\pm SD)
Zestril 10 Tablets (Astra Zeneca)	10mg	9.896 (\pm 0.627)	99.79 (\pm 0.277)

Results and Discussion

The amount of drug in Zestril Tablets was found to be 9.896 (\pm 0.627) mg/tab for Lisinopril & % assay^[31] was 99.79 %.

Summary and Conclusion

To develop a precise, linear, specific & suitable stability indicating RP-HPLC method for analysis of Lisinopril, different chromatographic conditions were applied & the results observed are presented in previous chapters. Isocratic elution is simple, requires only one pump & flat baseline separation for easy and reproducible results. So, it was preferred for the current study over gradient elution. In case of RP-HPLC various columns are available, but here Symmetry ODS RP C₁₈, 5 μ m, 15mmx4.6mm i.d. Column was preferred because using this column peak shape, resolution and absorbance were good. Discovery wavelength was chosen in the wake of examining the standard arrangement of medication more than 200 to 400 nm. From the U.V range of Lisinopril it is apparent that a large portion of the HPLC works can be proficient in the wavelength scope of 210-300 nm helpfully. Further, a stream rate of 1 ml/min and an infusion volume of 10 μ l were observed to be the best investigation. The outcome demonstrates the created technique is amazingly, one more reasonable strategy for measure and dependability related debasement examines which can help in the investigation of Lisinopril in various details.

References

- Greisdorf HF, O'Connor BC. Structures of image collections: from Chauvet-Pont-d'Arc to Flickr. Bloomsbury Publishing USA; c2007.
- Karger BL. HPLC: Early and Recent Perspectives. Journal of Chemical Education. 1997;74(1):45.
- Henry RA. The Early Days of HPLC at Dupont. Chromatography Online. Avanstar Communications Inc; c2009.
- Iler RK. The Chemistry of Silica. New York: John Wiley & Sons; c1979.
- Karger BL, Berry LV. Rapid liquid-chromatographic separation of steroids on columns heavily loaded with stationary phase. Clinical Chemistry. 1971;17(8):757-64.
- Giddings JC. Dynamics of Chromatography, Part I: Principles and Theory. New York: Marcel Dekker, Inc.; c1965. p. 281.
- Ettre C. Milestones in Chromatography: The Birth of Partition Chromatography (PDF). LCGC. 2001-2016;19(5):506-12.
- Martin AJP, Synge RLM. Separation of the higher monoamino-acids by counter-current liquid-liquid extraction: the amino-acid composition of wool. Biochemical Journal. 1941;35(1-2):91-121.
- Lindsay S, Kealey D. High-Performance Liquid Chromatography. Wiley. In: Theoretical and

experimental foundation for surface-coverage programming in gas-solid chromatography with an adsorbable carrier gas. Journal of the American Chemical Society. 1987;110(11):1090-1096.

- Journal of Pharmaceutical and Biomedical Analysis. 1999;21(2):371-382.
- Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 1). Tropical journal of pharmaceutical research. 2013;12(2):255-264.
- Sharma BK. Instrumental methods of chemical analysis. Krishna prakashan media; c1981.
- Snyder LR, Kirkland JJ, Glajch JL. Practical HPLC method development. John Wiley & Sons; c2012.
- U.S. Department of Health and Human Services FDA. Guidance for Industry: Analytical Procedure and Method Validation; c2000.
- Validation of analytical procedures: Methodology. ICH Harmonized Tripartite Guidelines. Geneva; c1996. p. 108.
- Ahuja S, Jespersen N, editors. Modern instrumental analysis. Elsevier; c2006.
- Petrozzi S. Practical Instrumental Analysis: Methods, Quality Assurance, and Laboratory Management. John Wiley & Sons; c2012.
- Kumudhavalli MV, Prakash C, Venkateshwarlu BS, Kumar M. A Novel Technique for the Quantification of Irinotecan HCl Injection. Research Journal of Pharmacy and Technology. 2019;12(12):6027-6030.
- Beckett AH, Stenlake JB, editors. Practical pharmaceutical chemistry: Part II fourth edition. A&C Black; c1988.
- Quality Assurance: Worth the Effort. Inforum. 2003, 7(4).
- Sethi PD. Quantitative analysis of drugs in pharmaceutical formulations. Unique Publishers; c1985.
- ICH Harmonized Tripartite Guidelines. Text on Validation of Analytical Procedures; c1994.
- Guideline IH. Validation of analytical procedures: text and methodology. Q2 (R1). 2005;1(20):05.
- Gupta V, Bhardwaj SK, Singla R. Development and validation of HPLC method - A review. International Research Journal of Pharmaceutical and Applied Sciences. 2012;2(4):17-25.
- Bhardwaj SK, Sharma MC, Jain D. A review: HPLC method development and validation. International Journal of Analytical and Bioanalytical Chemistry. 2015;5(3):76-81.
- Kromidas S, Kuss HJ, editors. Quantification in LC and GC: a practical guide to good chromatographic data. John Wiley & Sons; c2009.
- Sonawane LV, More HN, Bhatia MS. Bioanalytical method validation and its pharmaceutical application - A review. Pharmaceutica Analytica Acta. 2014;5(3):168-74.
- Guideline IH. Validation of analytical procedures: text and methodology. Q2 (R1). 2005;1(20):05.
- Chander V, Mohan M, Seth R, Singh P, Singh R, Gupta S. Development and validation of RP-HPLC method for the estimation of lisinopril in tablet dosage form. Analytical Chemistry Letters. 2012;2(5):309-313.
- Pawar VT, More HN, Bhatia MS. Development and validation of RP-HPLC method for the determination of lisinopril and amlodipine in bulk and multicomponent

- pharmaceutical cardiovascular dosage form. *Natural Volatiles & Essential Oils*. 2021;8(4):9441-9451.
31. Fahelebom KMS, Al-Tabakha MM, Eissa NAM, Obaid DEE, Sayed S. Development and validation of an RP-HPLC analytical method for determination of lisinopril in full and split tablets. *Research Journal of Pharmacy and Technology*. 2020;13(6):2647-2652.
DOI: 10.5958/0974-360X.2020.00470.9.
32. Babu KR, Sarma ESRS, Aruna kumari N, Raju GMJ, Sarma VM. Simple and stability indicating RP-HPLC assay method development and validation of lisinopril dihydrate in bulk and dosage form. *International Journal of Current Research and Academic Review*. 2015;3(4):226-233.